tv3326

Ladostigil (Ladostigil free base) 是一种具有口服活性的胆碱酯酶和脑选择性单胺氧化酶(MAO)双重抑制剂，对 MAO-B 和 AChE 具有抑制作用，IC50值分别为37.1和31.8μM。Ladostigil 具有抗炎、抗氧化和神经保护活性，可用于研究抑郁症和阿尔茨海默病。

Ladostigil hemitartrate (TV-3326) is a compound that acts as a dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO). It has IC50 values of 37.1 μM for MAO-B and 31.8 μM for AChE. In addition, Ladostigil hemitartrate possesses neuroprotective, antioxidant, and anti-inflammatory properties. It is commonly used in research relating to depression and Alzheimer's disease.

Ladostigil (TV-3326) hydrochloride 是一种口服有效的胆碱酯酶(cholinesterase)和脑选择性单胺氧化酶(MAO)的双重抑制剂，抑制MAO-B 和AChE 的IC50值分别为 37.1 和 31.8 μM。Ladostigil hydrochloride 具有神经保护，抗氧化和抗炎的作用，可用于抑郁症和阿尔茨海默症的研究。

Rasagiline-13C3is intended for use as an internal standard for the quantification of rasagiline by GC- or LC-MS. Rasagiline is an inhibitor of monoamine oxidase B (MAO-B; IC50= 4.43 nM for the rat brain enzyme).1It is selective for MAO-B over MAO-A (IC50= 412 nM for the rat brain enzyme). It inhibits serum and NGF withdrawal-induced apoptosis of PC12 cells when used at concentrations ranging from 0.01 to 100 μM.2Rasagiline inhibits rat brain MAO-Bin vivo(ED50= 0.1 mg kg).1It reduces cerebral edema in a mouse model of traumatic brain injury.2Rasagiline (0.1 mg kg) reduces cortical and hippocampal levels of full-length and soluble amyloid precursor protein (APP) in rats and mice. It also reduces α-synuclein-induced substantia nigral neuron loss and improves motor dysfunction in a mouse model of Parkinson's disease.3Formulations containing rasagiline have been used in the treatment of Parkinson's disease. 1.Youdim, M.B.H., Gross, A., and Finberg, J.P.Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase BBrit. J. Pharmacol.132(2)500-506(2001) 2.Youdim, M.B.H., and Weinstock, M.Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R) aminoindan-5-YL)-ethyl methyl carbamate]Cell. Mol. Neurobiol.21(6)555-573(2001) 3.Kang, S.S., Ahn, E.H., Zhang, Z., et al.α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's diseaseEMBO J.37(12)e98878(2018)